These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 1133166)
1. Pharmacokinetics of drugs in patients with the nephrotic syndrome. Gugler R; Shoeman DW; Huffman DH; Cohlmia JB; Azarnoff DL J Clin Invest; 1975 Jun; 55(6):1182-9. PubMed ID: 1133166 [TBL] [Abstract][Full Text] [Related]
2. Drug protein binding and the nephrotic syndrome. Gugler R; Azarnoff DL Clin Pharmacokinet; 1976; 1(1):25-35. PubMed ID: 797490 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Ganeval D; Fischer AM; Barre J; Pertuiset N; Dautzenberg MD; Jungers P; Houin G Clin Nephrol; 1986 Feb; 25(2):75-80. PubMed ID: 3698349 [TBL] [Abstract][Full Text] [Related]
4. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. Takamura N; Maruyama T; Chosa E; Kawai K; Tsutsumi Y; Uryu Y; Yamasaki K; Deguchi T; Otagiri M Drug Metab Dispos; 2005 Apr; 33(4):596-602. PubMed ID: 15640375 [TBL] [Abstract][Full Text] [Related]
5. Drug distribution in renal failure. Gibaldi M Am J Med; 1977 Apr; 62(4):471-4. PubMed ID: 851115 [TBL] [Abstract][Full Text] [Related]
6. Increased cyclosporine bioavailability induced by experimental nephrotic syndrome in rats. Medeiros M; Pérez-Urizar J; Pedraza-Chaverri J; Muñoz-Arizpe R; Castañeda-Hernández G Can J Physiol Pharmacol; 2007 May; 85(5):502-6. PubMed ID: 17632584 [TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic uremic patients with protein-poor diet and oral supply of essential amino acids. II. Clinical results of long-term treatment. Norée LO; Bergström J Clin Nephrol; 1975; 3(5):195-203. PubMed ID: 1149344 [TBL] [Abstract][Full Text] [Related]
8. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Perucca E; Cloyd J; Critchley D; Fuseau E Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564 [TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of cyclosporin A in patients with nephrotic syndrome]. Moulin B; Vernillet L; Dadoun C; Le Bigot JF; Godin M; Fillastre JP Nephrologie; 1989; 10(1):17-22. PubMed ID: 2716940 [TBL] [Abstract][Full Text] [Related]
10. Dietary protein intake does not affect IgG synthesis in patients with nephrotic syndrome. Giordano M; Lucidi P; De Feo P; DePascale E; Ciarambino T; Castellino P Nephrol Dial Transplant; 2004 Oct; 19(10):2494-8. PubMed ID: 15388819 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and interactions of oxandrolone, halo-fenate and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia. Schapel GJ; Edwards KD J Pharmacol Exp Ther; 1975 Jul; 194(1):274-84. PubMed ID: 1171221 [TBL] [Abstract][Full Text] [Related]
12. Regulation of renal sodium and water excretion in the nephrotic syndrome and cirrhosis of the liver. Jespersen B Dan Med Bull; 1997 Apr; 44(2):191-207. PubMed ID: 9151012 [TBL] [Abstract][Full Text] [Related]
13. The use of clofibrate in patients with renal insufficiency. Viikari J; Anttila M; Kasanen A Int J Clin Pharmacol Ther Toxicol; 1983 Feb; 21(2):77-80. PubMed ID: 6840929 [TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
15. Effect on nephrotic syndrome on absorption and disposition of prednisolone in children. Rocci ML; Assael BM; Appiani AC; Edefonti A; Jusko WJ Int J Pediatr Nephrol; 1982 Sep; 3(3):159-66. PubMed ID: 7141787 [TBL] [Abstract][Full Text] [Related]
16. Corticosteroids and ciclosporin A in idiopathic membranous nephropathy: higher remission rates of nephrotic syndrome and less adverse reactions than after traditional treatment with cytotoxic drugs. Goumenos DS; Katopodis KP; Passadakis P; Vardaki E; Liakopoulos V; Dafnis E; Stefanidis I; Vargemezis V; Vlachojannis JG; Siamopoulos KC Am J Nephrol; 2007; 27(3):226-31. PubMed ID: 17389782 [TBL] [Abstract][Full Text] [Related]
17. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Battino D; Croci D; Mamoli D; Messina S; Perucca E Epilepsy Res; 2004; 59(2-3):155-65. PubMed ID: 15246117 [TBL] [Abstract][Full Text] [Related]
18. Effects of muzolimine and of a combination of hydrochlorothiazide/triamterene in healthy subjects and in nephrotic patients. Riechers G; Futerova M; Hanisch M; Ritter W; Kühn K Z Kardiol; 1985; 74 Suppl 2():103-8. PubMed ID: 4002782 [TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics of adriamycin and antipyrine and its relation to the therapeutic and toxic effects. Preiss R; Matthias M; Sohr R; Brockmann B; Hüller H Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S79-88. PubMed ID: 3842695 [TBL] [Abstract][Full Text] [Related]
20. Effect of pregnancy on the pharmacokinetics of phenytoin in rats. Chou RC; Levy G J Pharmacol Exp Ther; 1984 May; 229(2):351-8. PubMed ID: 6716263 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]